These results are in concordance with previous studies showing that Tim3 expression is upregulated in tumor tissues and is associated with poor prognosis in patients with CRC, gastric cancer, prostate cancer, clear cell renal cancer, urothelial bladder cancer, and cervical cancer (29–34). Here, HAVCR2 is linked to prostate cancer.